These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10431580)

  • 1. [A study on the efficacy of combination chemoendocrine therapy consisting of cyclophosphamide, adriamycin, UFT, and tamoxifen for advanced or recurrent breast cancer].
    Yamaguchi S; Fukuda M; Ota T; Nakayama Y; Ogata H; Shimizu K; Nishikawa T; Adachi Y; Fukuma E
    Gan To Kagaku Ryoho; 1999 Jul; 26(8):1145-52. PubMed ID: 10431580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy for advanced breast cancer: cyclophosphamide, doxorubicin, UFT, and tamoxifen.
    Fukuda M; Yamaguchi S; Ohta T; Nakayama Y; Ogata H; Shimizu K; Nishikawa T; Adachi Y; Fukuma E
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):77-81. PubMed ID: 10442369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of combination therapy consisting of cyclophosphamide, adriamycin, UFT and oophorectomy/tamoxifen for advanced or recurrent breast cancer].
    Kiman K; Suzuki S; Satomi T; Sakonji M; Nihei M; Tanaka T; Kimijima I; Abe R
    Gan To Kagaku Ryoho; 1994 Oct; 21(14):2445-52. PubMed ID: 7944490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combination chemo-endocrine therapy of metastatic and stage IV breast cancer with cyclophosphamide, adriamycin, prednisolone and tamoxifen (CAPT)--with special reference to management of brain and liver metastasis].
    Nakamura Y; Kawaguchi M; Hata A; Watanabe H; Ueki Y; Oribe T; Koba F; Takamuku K
    Gan To Kagaku Ryoho; 1989 Feb; 16(2):243-50. PubMed ID: 2919892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adriamycin, cyclophosphamide, ftorafur and tamoxifen (ACFT) in patients with advanced breast cancer].
    Imajo K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Ozeki H; Nagamine D; Shinagawa K; Fukutani H
    Gan To Kagaku Ryoho; 1988 Jan; 15(1):121-6. PubMed ID: 3122665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combined chemoendocrine therapy using adriamycin, cyclophosphamide and high dose toremifene in patients with recurrent breast cancer].
    Wada N; Kobayashi H; Oka S; Ando J; Tamura H
    Gan To Kagaku Ryoho; 2002 Nov; 29(11):1935-42. PubMed ID: 12465393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of CAF'-endocrine therapy on advanced and recurrent breast cancer].
    Une Y; Sato Y; Kagaya H; Miyata S; Matsuoka S; Uchino J; Yakura Y
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2778-81. PubMed ID: 6548892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combination therapy with low dose adriamycin for advanced or recurrent breast cancer. Hokkaido Breast Cancer Treatment Study Group].
    Uchino J; Hata Y; Sasaki F; Takahashi H; Ogita M; Ohira S; Nakanishi M; Taguchi K; Inoue T; Konno T
    Gan To Kagaku Ryoho; 1993 Nov; 20(14):2157-64. PubMed ID: 8239680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [ACFT therapy using adriamycin, cyclophosphamide, tegafur and tamoxifen against progressive breast cancer].
    Watanabe Y; Tamura M; Meguro F
    Gan To Kagaku Ryoho; 1988 May; 15(5):1711-4. PubMed ID: 3130805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
    Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
    J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Systemic chemotherapy of mammary carcinoma: plasma and tissue concentrations of 5-fluorouracil and adriamycin, and result of CAF and CMF therapy of breast cancer].
    Murayama Y; Nagashima M
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):415-9. PubMed ID: 6546655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical usefulness of UFT and cyclophosphamide as salvage chemotherapy for patients with metastatic breast cancer].
    Watanabe O; Shimizu T; Imamura H; Kinoshita J; Okabe T; Ogawa K; Haga S
    Gan To Kagaku Ryoho; 2004 May; 31(5):717-21. PubMed ID: 15170979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer].
    Abe O; Izuo M; Enomoto K; Kubo K; Koyama H; Sakai K; Terasawa T; Tominaga T; Nomura Y
    Gan To Kagaku Ryoho; 1982 May; 9(5):866-73. PubMed ID: 7184431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical evaluation of adriamycin in advanced and recurrent breast cancer (No. 4)--Joint study by 30 institutes on the duration of remission using various maintenance therapies in patients treated with CAF. Clinical Study Group of Adriamycin for Breast Cancer in Japan].
    Nomura Y; Abe O; Izuo M; Inoue K; Enomoto K; Kubo K; Koyama H; Sakai K; Terasawa T; Tominaga T
    Gan To Kagaku Ryoho; 1988 Jun; 15(6):1863-71. PubMed ID: 3382238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
    Conti F; Carpano S; Sergi D; Di Lauro L; Amodio A; Vici P; Abbate MI; Ferranti FR; Viola G; Botti C; Foggi P; Sperduti I; Lopez M
    Clin Ter; 2007; 158(4):331-41. PubMed ID: 17953285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.
    Saeki T; Nomizu T; Toi M; Ito Y; Noguchi S; Kobayashi T; Asaga T; Minami H; Yamamoto N; Aogi K; Ikeda T; Ohashi Y; Sato W; Tsuruo T
    J Clin Oncol; 2007 Feb; 25(4):411-7. PubMed ID: 17179098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A randomized controlled study of (2'' R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer].
    Abe O; Tominaga T; Enomoto K; Abe R; Iino Y; Koyama H; Fujimoto M; Nomura Y; Tanaka T
    Gan To Kagaku Ryoho; 1986 Jun; 13(6):2160-8. PubMed ID: 3717960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines.
    Pieńkowski T; Jagiello-Gruszfeld A
    Int J Clin Pharmacol Res; 2001; 21(3-4):111-7. PubMed ID: 12067140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.